PHARMA MAR, S.A. 18/01/2018 19:00 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks CORAIL Phase III with Zepsire in resistant ovarian cancer has not met its primary endpoint. Número de registro: 260786